- Fingolimod in Real Clinical Practice2017 | First Faculty of Medicine
- Focussed on the pharmacological effect of fingolimod2020 | Faculty of Medicine in Hradec Králové
- Fingolimod in clinical practice: case reports2014 | Publication without faculty affiliation
- Fingolimod treatment of multiple sclerosis at any age2022 | Faculty of Medicine in Pilsen
- Fingolimod (drug)2011 | First Faculty of Medicine
- Multiple sclerosis: dimethyl fumarate and fingolimod - from clinical trials to clinical practice2017 | Faculty of Medicine in Hradec Králové
- Comments: Effect of fingolimod treatment in pediatric patients with multiple sclerosis - results of the PARADIGMS study focused on MR parameters2021 | Second Faculty of Medicine
- Long-term effect of immediate versus delayed treatment with fingolimod in young adult patients with RR-RS2020 | Faculty of Medicine in Hradec Králové
- Comparison of switch to fingolimod and continued treatment with glatiramer acetate or interferon Beta in patients with relapsing multiple sclerosis: Follow-up analysis of the EPOC clinical trial2015 | Publication without faculty affiliation
- A comparison of efficacy of subcutaneous interferon beta-1a 44 mu g, dimethyl fumarate and fingolimod in the real-life clinical practise - a multicenter observational study2018 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Long-term therapy of multiple sclerosis with fingolimod - results of 4.5-year extension study to TRANSFORMS2016 | Publication without faculty affiliation
- Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis2018 | First Faculty of Medicine
- Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation2023 | First Faculty of Medicine
- Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod2018 | First Faculty of Medicine
- The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies2021 | First Faculty of Medicine
- Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis2012 | Second Faculty of Medicine
- Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study2017 | First Faculty of Medicine
- How does fingolimod (gilenya(R)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?2013 | First Faculty of Medicine
- The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis2023 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis2015 | First Faculty of Medicine
- Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis2015 | First Faculty of Medicine
- Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study2012 | First Faculty of Medicine
- Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis2018 | First Faculty of Medicine
- Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study2012 | Second Faculty of Medicine
- Multiple Sclerosis Relapses Following Cessation of Fingolimod2022 | First Faculty of Medicine
- Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 months2022 | First Faculty of Medicine
- Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom2024 | First Faculty of Medicine
- Siponimod in the treatment of secondary - progressive multiple sclerosis - case report2022 | Faculty of Medicine in Hradec Králové
- Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study2017 | First Faculty of Medicine
- Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis2023 | First Faculty of Medicine, Third Faculty of Medicine